SP-D

サーファクタントプロテインD surfactant protein D

WordNet

1. the 4th letter of the Roman alphabet (同)d
2. the 19th letter of the Roman alphabet (同)s

PrepTutorEJDIC

1. deuteriumの化学記号
2. Shore Patrol / Specialist
3. sulfurの化学記号 / {略}South[ern]
4. (おもに人称代名詞・固有名詞(人名),thereの後で)had, wouldの短縮形 / (疑問文でwhere,what,whenの後で)didの短縮形;Where'd he go?=Where did he go?

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/09/14 23:06:48」(JST)

wiki en

[Wiki en表示]

Surfactant protein D
PDB rendering based on 1b08.
Available structures PDB Ortholog search: PDBe, RCSB List of PDB id codes 1B08, 1M7L, 1PW9, 1PWB, 2GGU, 2GGX, 2ORJ, 2ORK, 2OS9, 2RIA, 2RIB, 2RIC, 2RID, 2RIE, 3DBZ, 3G81, 3G83, 3G84, 3IKN, 3IKP, 3IKQ, 3IKR, 4E52, 4M17, 4M18
Identifiers
Symbols	SFTPD ; COLEC7; PSP-D; SFTP4; SP-D
External IDs	OMIM: 178635 MGI: 109515 HomoloGene: 2272 GeneCards: SFTPD Gene
Gene ontology Molecular function • protein binding • carbohydrate binding Cellular component • extracellular region • proteinaceous extracellular matrix • collagen trimer • extracellular space • lysosome • endocytic vesicle Biological process • regulation of cytokine production • receptor-mediated endocytosis • respiratory gaseous exchange • negative regulation of T cell proliferation • defense response to bacterium • surfactant homeostasis • negative regulation of interleukin-2 biosynthetic process • innate immune response • macrophage chemotaxis • lung alveolus development • positive regulation of phagocytosis • reactive oxygen species metabolic process Sources: Amigo / QuickGO
RNA expression pattern
More reference expression data
Orthologs
Species	Human	Mouse
Entrez	6441	20390
Ensembl	ENSG00000133661	ENSMUSG00000021795
UniProt	P35247	P50404
RefSeq (mRNA)	NM_003019	NM_009160
RefSeq (protein)	NP_003010	NP_033186
Location (UCSC)	Chr 10: 79.94 – 79.98 Mb	Chr 14: 41.17 – 41.19 Mb
PubMed search	[1]	[2]

Surfactant, pulmonary-associated protein D, also known as SFTPD or SP-D, is a protein which in humans is encoded by the SFTPD gene.

SFTPD is an innate immune system collectin.

Interactions

Surfactant protein D has been shown to interact with DMBT1.

See also

• pulmonary surfactant

References

External links

• Surfactant Protein D at the US National Library of Medicine Medical Subject Headings (MeSH)

Further reading

• Hansen S, Holmskov U (1998). "Structural aspects of collectins and receptors for collectins". Immunobiology 199 (2): 165–89. doi:10.1016/s0171-2985(98)80025-9. PMID 9777404. 
• Lu J, Willis AC, Reid KB (1992). "Purification, characterization and cDNA cloning of human lung surfactant protein D". Biochem. J. 284. 284 ( Pt 3): 795–802. PMC 1132609. PMID 1339284. 
• Ogasawara Y, Kuroki Y, Akino T (1992). "Pulmonary surfactant protein D specifically binds to phosphatidylinositol". J. Biol. Chem. 267 (29): 21244–9. PMID 1400434. 
• Rust K, Grosso L, Zhang V, Chang D, Persson A, Longmore W, Cai GZ, Crouch E (1991). "Human surfactant protein D: SP-D contains a C-type lectin carbohydrate recognition domain". Arch. Biochem. Biophys. 290 (1): 116–26. doi:10.1016/0003-9861(91)90597-C. PMID 1898081. 
• Kuroki Y, Shiratori M, Ogasawara Y, Tsuzuki A, Akino T (1991). "Characterization of pulmonary surfactant protein D: its copurification with lipids". Biochim. Biophys. Acta 1086 (2): 185–90. doi:10.1016/0005-2760(91)90006-4. PMID 1932100. 
• Crouch E, Persson A, Chang D, Heuser J (1994). "Molecular structure of pulmonary surfactant protein D (SP-D)". J. Biol. Chem. 269 (25): 17311–9. PMID 8006040. 
• Schaeffer E, Guillou F, Part D, Zakin MM (1993). "A different combination of transcription factors modulates the expression of the human transferrin promoter in liver and Sertoli cells". J. Biol. Chem. 268 (31): 23399–408. PMID 8226864. 
• Kölble K, Lu J, Mole SE, Kaluz S, Reid KB (1993). "Assignment of the human pulmonary surfactant protein D gene (SFTP4) to 10q22-q23 close to the surfactant protein A gene cluster". Genomics 17 (2): 294–8. doi:10.1006/geno.1993.1324. PMID 8406480. 
• Crouch E, Persson A, Chang D (1993). "Accumulation of surfactant protein D in human pulmonary alveolar proteinosis". Am. J. Pathol. 142 (1): 241–8. PMC 1886847. PMID 8424457. 
• Crouch E, Rust K, Veile R, Donis-Keller H, Grosso L (1993). "Genomic organization of human surfactant protein D (SP-D). SP-D is encoded on chromosome 10q22.2-23.1". J. Biol. Chem. 268 (4): 2976–83. PMID 8428971. 
• Rust K, Bingle L, Mariencheck W, Persson A, Crouch EC (1996). "Characterization of the human surfactant protein D promoter: transcriptional regulation of SP-D gene expression by glucocorticoids". Am. J. Respir. Cell Mol. Biol. 14 (2): 121–30. doi:10.1165/ajrcmb.14.2.8630261. PMID 8630261. 
• Bonaldo MF, Lennon G, Soares MB (1996). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Res. 6 (9): 791–806. doi:10.1101/gr.6.9.791. PMID 8889548. 
• Holmskov U, Lawson P, Teisner B, Tornoe I, Willis AC, Morgan C, Koch C, Reid KB (1997). "Isolation and characterization of a new member of the scavenger receptor superfamily, glycoprotein-340 (gp-340), as a lung surfactant protein-D binding molecule". J. Biol. Chem. 272 (21): 13743–9. doi:10.1074/jbc.272.21.13743. PMID 9153228. 
• Botas C, Poulain F, Akiyama J, Brown C, Allen L, Goerke J, Clements J, Carlson E, Gillespie AM, Epstein C, Hawgood S (1998). "Altered surfactant homeostasis and alveolar type II cell morphology in mice lacking surfactant protein D". Proc. Natl. Acad. Sci. U.S.A. 95 (20): 11869–74. doi:10.1073/pnas.95.20.11869. PMC 21732. PMID 9751757. 
• Håkansson K, Lim NK, Hoppe HJ, Reid KB (1999). "Crystal structure of the trimeric alpha-helical coiled-coil and the three lectin domains of human lung surfactant protein D". Structure 7 (3): 255–64. doi:10.1016/S0969-2126(99)80036-7. PMID 10368295. 
• Holmskov U, Mollenhauer J, Madsen J, Vitved L, Gronlund J, Tornoe I, Kliem A, Reid KB, Poustka A, Skjodt K (1999). "Cloning of gp-340, a putative opsonin receptor for lung surfactant protein D". Proc. Natl. Acad. Sci. U.S.A. 96 (19): 10794–9. doi:10.1073/pnas.96.19.10794. PMC 17962. PMID 10485905. 
• Lausen M, Lynch N, Schlosser A, Tornoe I, Saekmose SG, Teisner B, Willis AC, Crouch E, Schwaeble W, Holmskov U (1999). "Microfibril-associated protein 4 is present in lung washings and binds to the collagen region of lung surfactant protein D". J. Biol. Chem. 274 (45): 32234–40. doi:10.1074/jbc.274.45.32234. PMID 10542261. 
• Madsen J, Kliem A, Tornoe I, Skjodt K, Koch C, Holmskov U (2000). "Localization of lung surfactant protein D on mucosal surfaces in human tissues". J. Immunol. 164 (11): 5866–70. doi:10.4049/jimmunol.164.11.5866. PMID 10820266. 
• Zhang L, Ikegami M, Crouch EC, Korfhagen TR, Whitsett JA (2001). "Activity of pulmonary surfactant protein-D (SP-D) in vivo is dependent on oligomeric structure". J. Biol. Chem. 276 (22): 19214–9. doi:10.1074/jbc.M010191200. PMID 11278637. 

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 新生児における呼吸促迫症候群の病態生理および臨床症状 pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn
• 2. サーファクタント機能障害の遺伝性疾患 genetic disorders of surfactant dysfunction
• 3. 成人における肺胞蛋白症の臨床症状および病因 clinical manifestations and etiology of pulmonary alveolar proteinosis in adults
• 4. マンノース結合レクチン mannose binding lectin
• 5. 髄膜炎菌感染の疫学 epidemiology of neisseria meningitidis infection

English Journal

• Recombinant porcine surfactant protein D inhibits influenza A virus replication ex vivo.

• Hillaire ML1, van Eijk M2, Vogelzang-van Trierum SE1, Fouchier RA1, Osterhaus AD3, Haagsman HP2, Rimmelzwaan GF4.Author information 1Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands.2Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.3Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands; Viroclinics Biosciences BV, Rotterdam, The Netherlands.4Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands; Viroclinics Biosciences BV, Rotterdam, The Netherlands. Electronic address: g.rimmelzwaan@erasmusmc.nl.AbstractInfluenza is a major burden to public health. Due to high mutation rates and selection pressure, mutant viruses emerge which are resistant to currently used antiviral drugs. Therefore, there is a need for the development of novel classes of antiviral drugs that suffer less from the emergence of resistant viruses. Antiviral drugs based on collectin-like surfactant protein D (SP-D) may fulfil these requirements. Especially porcine SP-D displays strong antiviral activity to influenza A viruses. In the present study the antiviral activity of recombinant porcine SP-D was investigated in ex vivo cultures of respiratory tract tissue infected with human influenza A virus of the H3N2 subtype. Porcine SP-D has antiviral activity in these test systems. It is suggested that porcine SP-D may be used as a venue to develop a novel class of antiviral drugs.
• Virus research.Virus Res.2014 Mar 6;181C:22-26. doi: 10.1016/j.virusres.2013.12.032. Epub 2014 Jan 1.
• Influenza is a major burden to public health. Due to high mutation rates and selection pressure, mutant viruses emerge which are resistant to currently used antiviral drugs. Therefore, there is a need for the development of novel classes of antiviral drugs that suffer less from the emergence of resi
• PMID 24389095

• Smoking and polymorphisms of genes encoding mannose-binding lectin and surfactant protein-D in patients with rheumatoid arthritis.

• Kristiansen M, Frisch M, Madsen HO, Garred P, Jacobsen S.Author information Department of Rheumatology, 4242, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark.AbstractTo investigate whether polymorphisms in genes coding for mannose-binding lectin (MBL) and surfactant protein-D (SP-D) are associated directly or by interaction with smoking with rheumatoid arthritis (RA), anti-citrullinated peptide antibody (ACPA) positive RA, and erosive RA. MBL2 genotypes, SFTPD genotype at codon 11, and HLA-shared epitope were determined in 456 patients with rheumatoid arthritis and 533 sex- and age-matched controls. Patients were grouped according to the presence of ACPA antibodies and RA-associated bone erosions and sub-stratified according to smoking status as never or ever smokers. Odds ratios with 95 % confidence interval (OR, 95 % CI) were calculated using multiple logistic regression analyses controlling for shared epitope. The low-producing SFTPD genotype was not associated with risk of RA or ACPA positive RA, but with erosive disease in the RA patients (OR = 1.8; 95 % CI 1.1-3.0) particularly in RA ever smokers (OR = 2.4; 95 % CI 1.3-4.3). The high-producing MBL2 genotype YA/YA was associated with ACPA positive RA (OR = 1.4; 95 % CI 1.0-1.9) and erosive joint disease in RA ever smokers (OR = 1.8; 95 % CI 1.1-3.0). Genetic disposition for low SP-D was not associated with RA but with erosive RA by interaction with smoking. The genetic disposition for high MBL production was associated with ACPA positive RA irrespective of shared epitope. The findings need to be replicated but do as such offer further explanations for the clinical heterogeneity of RA.
• Rheumatology international.Rheumatol Int.2014 Mar;34(3):373-80. doi: 10.1007/s00296-013-2904-z. Epub 2013 Nov 22.
• To investigate whether polymorphisms in genes coding for mannose-binding lectin (MBL) and surfactant protein-D (SP-D) are associated directly or by interaction with smoking with rheumatoid arthritis (RA), anti-citrullinated peptide antibody (ACPA) positive RA, and erosive RA. MBL2 genotypes, SFTPD g
• PMID 24264011

• Genetic Polymorphisms of Surfactant Protein D rs2243639, Interleukin (IL)-1β rs16944 and IL-1RN rs2234663 in Chronic Obstructive Pulmonary Disease, Healthy Smokers, and Non-Smokers.

• Issac MS, Ashur W, Mousa H.Author information Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, El Saray St., El Manial, 11956, Cairo, Egypt, mariannesamir@kasralainy.edu.eg.AbstractBACKGROUND AND OBJECTIVES: Chronic obstructive pulmonary disease (COPD) is a complex chronic inflammatory disease that involves the activity of various inflammatory cells and mediators. It has been suggested that susceptibility to COPD is, at least in part, genetically determined. The primary aim of this study was to investigate the association between surfactant protein D (SFTPD) rs2243639, interleukin (IL)-1β rs16944 and IL-1 receptor antagonist (IL-1RN) rs2234663 gene polymorphisms and COPD susceptibility, as well as examining the association between the various IL-1RN/IL-1β haplotypes and pulmonary function tests (PFT). Secondly, we aimed to examine the influence of SFTPD rs2243639 polymorphism on serum surfactant protein D (SP-D) level.
• Molecular diagnosis & therapy.Mol Diagn Ther.2014 Feb 7. [Epub ahead of print]
• BACKGROUND AND OBJECTIVES: Chronic obstructive pulmonary disease (COPD) is a complex chronic inflammatory disease that involves the activity of various inflammatory cells and mediators. It has been suggested that susceptibility to COPD is, at least in part, genetically determined. The primary aim of
• PMID 24504887

Japanese Journal

• APP-078 尿路におけるサーファクタント蛋白質(SP-A、SP-D)の感染防御 : 尿路病原性大腸菌の尿路上皮への接着阻害(総会賞応募ポスター,第99回日本泌尿器科学会総会)

• 栗村 雄一郎,西谷 千明,橋本 次朗,高橋 聡,有木 茂,高橋 素子,黒木 由夫,塚本 泰司
• 日本泌尿器科學會雜誌 102(2), 331, 2011-03-20
• NAID 110008612022

• Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.

• Yamaguchi Hiroyuki,Soda Hiroshi,Nakamura Yoichi,Takasu Mineyo,Tomonaga Nanae,Nakano Hirofumi,Doi Seiji,Nakatomi Katsumi,Nagashima Seiji,Takatani Hiroshi,Fukuda Minoru,Hayashi Tomayoshi,Tsukamoto Kazuhiro,Kohno Shigeru
• Cancer chemotherapy and pharmacology 67(2), 331-338, 2011-02
• … In this study, we evaluated prospectively whether surfactant protein-A (SP-A) and -D (SP-D) may be new conventional predictors of the efficacy of gefitinib treatment. … METHODS: We measured serum SP-A and SP-D levels on days 0 and 29 in 40 patients with advanced NSCLC treated with 250 mg gefitinib daily. …
• NAID 120002139476

Related Links

• 肺サーファクタント プロテインD(SP-D)

SP -D は現在のところヒトにおいて肺以外の臓器、細胞での発現は報告されておらず,きわめて肺に特異的な物質であるといわれている.近年このSP -D が血液中にも存在していることが判明し,肺以外では産性,分泌されないことから血清中SP ...

• TOP of SP-D

地元・北陸より極上のポップスを発信する、アコースティックデュオ。 SP-D（スピィーディ） ... SAYONARA takeshi ver SAYONARA takeshi ver / SP-D takeshi DOWNLOAD版 販売 価格 200円 250円【ハイレゾ音源】

Related Pictures

---

★リンクテーブル★

国試過去問	「108D058」「114A049」
リンク元	「肺胞蛋白症」「サーファクタントプロテインD」「サーファクタント関連タンパク質」「SP-A」
関連記事	「D」「SP」「S」

「108D058」

　　[★]

• 72歳の女性。咳と労作時息切れとを主訴に来院した。 1年前から乾性咳嗽と労作時呼吸困難とを自覚し、時に朝方のこわばりも自覚していた。 1か月前から増悪するため受診した。既往歴に特記すべきことはない。意識は清明。身長 162 cm、体重62 kg。体温 36.8℃。脈拍 76/分、整。血圧 130/60 mmHg。皮疹を認めない。心音に異常を認めない。両側の背下部に fine cracklesを聴取する。両側手指の変形、腫脹および圧痛は認めない。血液所見：赤血球 269万、 Hb 8.7 g/dl、Ht 25%、白血球9,700(桿状核好中球 5%、分葉核好中球 74%、好酸球 2%、単球 4%、リンパ球 13% )、血小板 22万。血液生化学所見：総蛋白 6.8 g/dl、アルブミン 2.8 g/dl、AST 22 IU/l、 ALT 12 IU/l、LD 253 IU/l(基準 176～ 353)、尿素窒素 18 mg/dl、クレアチニン 1.1mg/dl、尿酸 5.9 mg/dl、脳性ナトリウム利尿ペプチド〈BNP〉10 pg/ml(基準 18.4以下 )、 KL-6 996 U/ml(基準 500未満 )。免疫血清学所見： CRP 8.7 mg/dl、リウマトイド因子〈RF〉315 IU/ml(基準 20未満 )、抗 CCP抗体 65 U/ml(基準 4.5未満 )、抗核抗体 80倍 (基準 20以下 )、サーファクタントプロテインD〈SP-D〉178 ng/ml(基準 0～109)。動脈血ガス分析 ( room air)： pH 7.47、PaCO2 34 Torr、PaO2 63 Torr、HCO3-24 mEq/l。呼吸機能検査所見：% VC 63%、 FEV1% 79%、% DLco 35.6%。胸部エックス線写真 (別冊 No.29Ａ)と肺野条件の胸部単純 CT(別冊 No.29Ｂ)とを別に示す。
• 治療薬として適切なのはどれか。2つ選べ。

• a　利尿薬
• b　抗菌薬
• c　免疫抑制薬
• d　副腎皮質ステロイド
• e　ロイコトリエン受容体拮抗薬

[正答]

CD

※国試ナビ4※　［108D057］←［国試_108］→［108D059］

「114A049」

　　[★]

• 78歳の男性。労作時呼吸困難を主訴に来院した。半年前から労作時呼吸困難を自覚し、2週前から増悪しているという。意識は清明。体温 37.0℃。脈拍 100/分、整。血圧 146/84mmHg。呼吸数 24/分。SpO2 88%(room air)。心音に異常を認めない。両側の背部にfine cracklesを聴取する。下腿に浮腫を認めない。胸部エックス線写真(別冊No.20Ａ)及び胸部CT(別冊No.20Ｂ)を別に示す。
• 認められる可能性が高いのはどれか。

• a　一秒率低下
• b　PaCO2上昇
• c　A-aDO2開大
• d　血清LD低下
• e　血中サーファクタントプロテインD(SP-D)低下

[正答]

C

※国試ナビ4※　［114A048］←［国試_114］→［114A050］

「肺胞蛋白症」

　　[★]

英

alveolar proteinosis、pulmonary alveolar proteinosis, PAP

同

肺胞タンパク症、肺胞タンパク質症

[show details]

肺胞蛋白症 : 約 102,000 件
肺胞蛋白質症 : 49 件
肺胞タンパク症 : 約 40,400 件
肺胞タンパク質症 : 49 件

病因

• 肺胞貯留物には肺胞マクロファージが認められ、これの機能異常によるものと考えられている。

病態

• 肺胞腔内に、ジパルミトイルホスファチジルコリン(DPPC)、SP-A、SP-Dが蓄積することで、呼吸器症状を呈する。

症状

• 進行性の労作時呼吸困難、咳嗽(喀痰を伴わない)、疲労、体重減少、軽度発熱。初発症状は呼吸困難(55-80%の症例で見られる)。(参考1)

身体所見

参考1

• チアノーゼ、ばち指(いずれも25%の例で見られる)。
• crackles(50%の例で見られる)

検査

• 胸部単純X線：両肺野対称性、中下肺野中心に浸潤影。両肺門から広がるbutterfly shadow
• 胸部単純CT：不均等なすりガラス陰影。メロンの皮様網目状陰影、crazy paving appearance

[show details]

• 肺胞洗浄液 BAL：白濁液。

[show details]

治療

• DLCO低下、PaO2低下や臨床症状の悪化が見られる場合、肺胞洗浄療法
• ステロイドは無効であり禁

参考

• 1. [charged] 成人における肺胞蛋白症の臨床症状および病因 - uptodate [1]
• 2. [charged] 成人における肺胞蛋白症の診断および治療 - uptodate [2]
• 3. [charged] 小児における肺胞蛋白症 - uptodate [3]

国試

• 105I063

「サーファクタントプロテインD」

　　[★]

英

surfactant protein D SP-D

関

KL-6, SP-A。サーファクタントプロテイン

概念

• II型肺胞上皮細胞が分泌するサーファクトプロテインの一種。
• 肺の線維化のマーカーとして用いられる。

基準値

• 110ng/ml未満

意義

臨床検査データブックより引用

高値

• 特発性間質性肺炎(87%)、膠原病関連間質性肺臓炎(71%)、肺胞蛋白症(80%)、過敏性肺臓炎、放射線肺臓炎

可能性

• サルコイドーシス、肺結核、びまん性汎細気管支炎、慢性肺気腫、気管支拡張症、塵肺、細菌性肺炎

低値

• 健常者、気管支喘息

「サーファクタント関連タンパク質」

　　[★]

英

surfactant protein

関

[[]]

• surfactant protein A SP-A
• surfactant protein B SP-B
• surfactant protein C SP-C
• surfactant protein D SP-D

「SP-A」

　　[★]

英

surfactant protein A

同

サーファクタントプロテインA

関

KL-6, SP-D

「D」

　　[★]

• アスパラギン酸
• ジヒドロウリジン
• 遠位の distal,
• うつ病 depression
• 下行結腸 descending colon(大腸内視鏡検査の結果を記載するときに用いる)

　 　

「SP」

　　[★]

• 標準模擬患者 模擬患者 standardized patient
• サブスタンスP
• 肺サーファクタントタンパク質
• station方式
• 同時視 simultaneous perception

　

「S」

　　[★]

• セリン serine
• 胸骨上縁